Inhibition of Cellular and Animal Inflammatory Disease Models by NF-κB Inhibitor DHMEQ

Abstract

General inflammatory diseases include skin inflammation, rheumatoid arthritis, inflammatory bowel diseases, sepsis, arteriosclerosis, and asthma. Although these diseases have been extensively studied, most of them are still difficult to treat. Meanwhile, NF-κB is a transcription factor promoting the expression of many inflammatory mediators. NF-κB is likely to be involved in the mechanism of most inflammatory diseases. We discovered a specific NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), about 20 years ago by molecular design from a natural product. It directly binds to and inactivates NF-κB components. It has been widely used to suppress cellular and animal inflammatory disease models and was shown to be potent in vivo anti-inflammatory activity without any toxicity. We have prepared ointment of DHMEQ for the treatment of severe skin inflammation. It inhibited inflammatory cytokine expressions and lowered the clinical score in mouse models of atopic dermatitis. Intraperitoneal (IP) administration of DHMEQ ameliorated various disease models of inflammation, such as rheumatoid arthritis, sepsis, and also graft rejection. It has been suggested that inflammatory cells in the peritoneal cavity would be important for most peripheral inflammation. In the present review, we describe the synthesis, mechanism of action, and cellular and in vivo anti-inflammatory activities and discuss the clinical use of DHMEQ for inflammatory diseases.

Euphorbia factor L3 ameliorates rheumatoid arthritis by suppressing the inflammatory response by targeting Rac family small GTPase 1

“…Previous studies demonstrated that targeting the NF-κB signaling pathway could prevent the progression of inflammation and ameliorate bone erosion in arthritis mouse models [ 33 , 34 ]. Moreover, some clinical drugs, such as iguratimod, show sustained efficacy in RA by inactivating NF-κB [ 35–37 ].…”

Comprehensive analysis of the expression and prognosis for APOE in malignancies: A pan-cancer analysis

“…However, for many tumors the prognosis is difficult to obtain from the expression level of APOE alone. In addition, previous research indicated that diet could impact the levels of APOE expression [29,30].…”

Classic Signaling Pathways in Alveolar Injury and Repair Involved in Sepsis-Induced ALI/ARDS: New Research Progress and Prospect

“…Several studies have shown that HIF-1 α can activate the NF- κ B pathway and increase the secretion of cytokines such as TNF- α and IL-6 in the early stages of a cytokine storm [ 25 , 26 ]. In addition, dehydroxymethylepoxyquinomicin (DHMEQ) can inhibit NF- κ B activation and reduce inflammatory cytokine expression [ 27 ]. As shown in Figure 2 , NF- κ B pathway can promote autoimmunity and inflammation when it is aberrantly activated in different cell types.…”